Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL511745 | 0.77 | TSHR (0.36) | TSHRLTA4HALDH1A1CA4SRC | |
| SCHEMBL8885 | 0.77 | LTA4H (0.50) | TSHRLTA4HALDH1A1CA4CA1 | |
| Hydrochloric Acid SCHEMBL693111 | 0.75 | LTA4H (0.47) | KMT2ATSHRLTA4HALDH1A1CA4 | |
| SCHEMBL6113933 | 0.74 | CA4 (0.36) | TSHRLTA4HCA4 | |
| SCHEMBL9747855 | 0.72 | TSHR (0.38) | LMNAGAAKMT2ATSHRLTA4H | |
| SCHEMBL1797563 | 0.72 | LMNA (0.33) | LMNAGAAKMT2ATSHRLTA4H | |
| SCHEMBL29544396 | 0.72 | LTA4H (0.45) | TSHRLTA4HALDH1A1CA4CA1 | |
| SCHEMBL29102439 | 0.71 | PARP10 (0.37) | LMNAGAAKMT2ATSHRALDH1A1 | |
| SCHEMBL4735958 | 0.69 | CA4 (0.50) | LMNATSHRLTA4HCA4CA1 | |
| SCHEMBL1162702 | 0.69 | LTA4H (0.41) | TSHRLTA4HALDH1A1CA4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111788484-B | Method for stabilizing protein contained in sample, solution for stabilizing protein contained in sample | 荣研化学株式会社 | 2024-11-19 | — | — | CN | claimed |
| US-10155676-B2 | Process for extracting a surfactant using a boronic acid modified material | BICKER KEVIN L (US) | 2018-12-18 | — | — | US | claimed |
| US-20170057840-A1 | Process For Extracting A Surfactant Using A Boronic Acid Modified Material | BICKER KEVIN L (US) | 2017-03-02 | — | — | US | claimed |
| US-20120322145-A1 | THREE-DIMENSIONAL CELL ADHESION MATRIX | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-12-20 | — | — | US | claimed |
| US-20120141384-A1 | ANTIBACTERIAL CONJUGATED BORONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2012-06-07 | — | — | US | claimed |
| WO-2010148346-A2 | THREE-DIMENSIONAL CELL ADHESION MATRIX | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-23 | — | — | WO | claimed |
| US-20240228500-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. | 2024-07-11 | — | — | US | disclosed |
| US-12029791-B2 | Therapeutic conjugates | TOTUS MEDICINES INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024086664-A2 | COVALENT INHIBITORS OF WILD-TYPE AND MUTANT PI3K AND METHOD OF USES THEREOF | TOTUS MEDICINES INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4308121-A1 | THERAPEUTIC CONJUGATES | Totus Medicines Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230405135-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2023183936-A2 | COMBINATION THERAPY OF A PI3K INHIBITOR AND KRAS INHIBITOR AND METHODS OF USE THEREOF | TOTUS MEDICINES INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4210766-A1 | THERAPEUTIC CONJUGATES | Totus Medicines Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| EP-1751089-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| EP-1725236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005086873-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1140941-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039131-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179131-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRNA3 | LMNA 3932/4885GAA 4650/4885KMT2A 2049/4885 |
| US-20120141384-A1 | ANTIBACTERIAL CONJUGATED BORONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABCB11, SLC10A2, SLC10A1 | LMNA 2718/4885GAA 25/4885KMT2A 3669/4885 |
| US-12029791-B2 | Therapeutic conjugates | CD47, CD44, EPCAM | LMNA 2481/4885GAA 348/4885KMT2A 2318/4885 |
| US-20240228500-A1 | THERAPEUTIC CONJUGATES | CD47, CD44, EPCAM | LMNA 2481/4885GAA 348/4885KMT2A 2318/4885 |
| US-20230405135-A1 | THERAPEUTIC CONJUGATES | CD47, CD44, EPCAM | LMNA 2481/4885GAA 348/4885KMT2A 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.